12 Jun'26 Portfolio
A very diversified global portfolio that is underweight technology
Vish (Hunting Alphas)
Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy (Archive)
Wegovy pill expands US obesity share, but cash flow limits and GLP‑1 competition constrain upside.
AMD: The Market Is Still Underpricing Its AI CPU Super Cycle (Archive, Full Access)
AMD’s agentic-AI-driven server CPU and GPU surge is still mispriced by markets.
Nvidia Looks Undervalued, But That Doesn't Make Me More Bullish (Archive)
Undervalued juggernaut facing emerging margin and custom-chip headwinds despite explosive growth.
Adobe: I'm Not Expecting Much In Q2 And Beyond (Archive)
AI cannibalization and slowing earnings growth cap upside despite a cheap headline valuation multiple.
Oracle: Risks To Watch For In Q4 And Beyond (Archive)
Oracle’s OpenAI‑heavy backlog and aggressive AI capex create long‑dated, uncertain returns.
5 Jun'26 Portfolio
Increasing exposure to healthcare and REITs